Finnhub
Presentation Operator MessageOperator Good afternoon, and welcome to the PDS Biotechnology Virtual KOL Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will
Yahoo
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET PRINCETON, N.J., June 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it w
Finnhub
PDS Biotechnology Corporation announced publication of three Versamune HPV abstracts now available on the 2025 American Society of Clinical Oncology Annual Meeting website. A p16-positive test result...
Yahoo
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 is the only ongoing Phase 3 clinical trial exclusively addressing 1L r/m HPV16-positive HNSCC PRINCETON, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunoth
Yahoo
PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company’s latest abstracts reveal that patients with HPV16-positive recurrent/metastatic head and neck cancer (HNSCC) treated with PDS0101 and pembrolizumab achieved a median overall survival (mOS) of 39.3 months, more […]
Yahoo
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Trial-in-progress currently enrolling patients Conference call on Friday, May 23 at 8:00 a.m. ET to discuss ASCO abstract data sets PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ARCT | 48.21% | $352.30M | -39.53% | 0.00% |
| RXRX | 46.60% | $2.09B | -28.35% | 0.00% |
| NNOX | 45.80% | $326.14M | -25.33% | 0.00% |
| COHU | 44.36% | $912.85M | -41.28% | 0.00% |
| DYN | 44.17% | $986.63M | -74.95% | 0.00% |
| CRNX | 43.30% | $2.66B | -37.57% | 0.00% |
| DNLI | 43.05% | $2.03B | -35.83% | 0.00% |
| IMNM | 43.03% | $736.56M | -27.65% | 0.00% |
| NRIX | 42.83% | $892.72M | -38.14% | 0.00% |
| IDYA | 42.37% | $1.85B | -37.37% | 0.00% |
| ATXS | 42.15% | $306.44M | -39.46% | 0.00% |
| RGNX | 41.69% | $414.70M | -23.44% | 0.00% |
| CEVA | 41.08% | $520.18M | +16.25% | 0.00% |
| KLIC | 40.94% | $1.88B | -27.34% | 2.28% |
| OCUL | 40.92% | $1.45B | +36.23% | 0.00% |
| ABCL | 40.91% | $1.04B | +25.99% | 0.00% |
| SYRE | 40.85% | $934.88M | -34.89% | 0.00% |
| APGE | 40.69% | $2.63B | +15.83% | 0.00% |
| BDTX | 40.65% | $141.02M | -41.09% | 0.00% |
| ACMR | 40.37% | $1.70B | +16.50% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 54.24% | $4.84B | 0.35% |
| ARKG | 52.38% | $1.02B | 0.75% |
| GNOM | 51.42% | $44.38M | 0.5% |
| IBB | 49.14% | $5.28B | 0.45% |
| PTH | 49.09% | $100.70M | 0.6% |
| IWC | 46.27% | $817.74M | 0.6% |
| PINK | 45.77% | $129.96M | 0.5% |
| PBE | 45.22% | $223.86M | 0.58% |
| IWO | 45.03% | $11.53B | 0.24% |
| FBT | 44.01% | $1.01B | 0.54% |
| FFTY | 43.99% | $79.79M | 0.8% |
| KOMP | 43.82% | $2.28B | 0.2% |
| ERTH | 43.29% | $136.29M | 0.67% |
| IDRV | 43.27% | $148.05M | 0.47% |
| PBW | 42.92% | $268.39M | 0.65% |
| QQQJ | 42.89% | $618.04M | 0.15% |
| DRIV | 42.62% | $309.46M | 0.68% |
| XT | 42.58% | $3.39B | 0.46% |
| ROBT | 42.27% | $493.51M | 0.65% |
| BATT | 42.01% | $61.71M | 0.59% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -15.78% | $24.29B | +35.36% | 1.09% |
| ED | -15.19% | $36.31B | +13.27% | 3.35% |
| GO | -15.02% | $1.27B | -41.23% | 0.00% |
| DUK | -12.52% | $92.39B | +19.10% | 3.55% |
| PULM | -12.51% | $24.14M | +230.50% | 0.00% |
| KMB | -12.03% | $43.67B | -4.62% | 3.76% |
| MO | -10.29% | $97.93B | +26.25% | 6.95% |
| AWK | -10.23% | $27.80B | +10.98% | 2.21% |
| CME | -10.21% | $99.25B | +39.75% | 3.87% |
| AEP | -10.01% | $55.76B | +19.14% | 3.55% |
| CL | -9.97% | $74.59B | -4.24% | 2.20% |
| T | -9.85% | $207.81B | +53.45% | 3.83% |
| KR | -9.68% | $47.17B | +41.48% | 1.81% |
| IMNN | -9.29% | $15.87M | -37.00% | 0.00% |
| BTCT | -8.48% | $22.63M | +43.33% | 0.00% |
| SO | -8.29% | $101.44B | +19.02% | 3.16% |
| CAG | -7.91% | $10.05B | -25.70% | 6.63% |
| K | -7.90% | $27.71B | +40.85% | 2.85% |
| TEF | -7.65% | $30.02B | +27.27% | 6.13% |
| EXC | -7.37% | $43.82B | +25.72% | 3.63% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MOH | -0.02% | $16.60B | +4.89% | 0.00% |
| REYN | 0.02% | $4.58B | -20.94% | 4.24% |
| FUBO | 0.06% | $1.29B | +187.79% | 0.00% |
| CABO | 0.06% | $795.04M | -59.44% | 6.27% |
| CLX | -0.06% | $15.23B | -7.50% | 3.92% |
| SAFT | -0.06% | $1.18B | +5.51% | 4.53% |
| LITB | -0.11% | $22.07M | -77.41% | 0.00% |
| SHEN | 0.13% | $768.55M | -17.10% | 0.71% |
| USM | -0.14% | $5.46B | +16.18% | 0.00% |
| CNA | 0.21% | $12.58B | +6.50% | 3.90% |
| DG | -0.23% | $25.37B | -10.94% | 2.05% |
| VSA | 0.23% | $8.76M | -18.25% | 0.00% |
| D | 0.24% | $49.16B | +18.77% | 4.67% |
| SIGI | -0.26% | $5.30B | -6.77% | 1.73% |
| PNW | -0.31% | $10.85B | +19.48% | 3.95% |
| PRA | 0.32% | $1.17B | +87.59% | 0.00% |
| DNUT | 0.37% | $544.85M | -67.45% | 4.30% |
| PM | -0.39% | $276.33B | +74.67% | 3.05% |
| NTZ | -0.42% | $41.64M | -22.22% | 0.00% |
| ACI | -0.47% | $12.20B | +8.96% | 2.48% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SPTS | 0.04% | $5.77B | 0.03% |
| IYK | 0.25% | $1.45B | 0.4% |
| FXY | 0.28% | $820.31M | 0.4% |
| AGZD | 0.42% | $102.60M | 0.23% |
| IBDQ | 0.43% | $2.99B | 0.1% |
| FMF | -0.47% | $157.12M | 0.95% |
| UNG | -0.57% | $388.31M | 1.06% |
| PSQA | 0.63% | $35.43M | 0.2% |
| STPZ | 0.68% | $450.05M | 0.2% |
| SHV | 0.77% | $20.67B | 0.15% |
| UTWO | 1.25% | $379.27M | 0.15% |
| IBTG | 1.25% | $1.92B | 0.07% |
| CARY | 1.53% | $347.36M | 0.8% |
| FTSD | 1.56% | $231.68M | 0.25% |
| IBTH | 1.67% | $1.60B | 0.07% |
| CCOR | -1.92% | $51.54M | 1.18% |
| BSCP | 2.12% | $3.28B | 0.1% |
| DFNM | 2.32% | $1.57B | 0.17% |
| BIL | -2.42% | $42.84B | 0.1356% |
| IBMN | 2.56% | $446.95M | 0.18% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -40.50% | $295.67M | 1.43% |
| VIXY | -27.50% | $165.58M | 0.85% |
| TAIL | -25.05% | $99.49M | 0.59% |
| USFR | -13.11% | $18.59B | 0.15% |
| TFLO | -12.51% | $6.83B | 0.15% |
| IVOL | -11.16% | $348.25M | 1.02% |
| UUP | -9.35% | $209.45M | 0.77% |
| JMST | -9.17% | $4.06B | 0.18% |
| TPMN | -8.57% | $30.70M | 0.65% |
| USDU | -8.50% | $163.19M | 0.5% |
| CTA | -5.49% | $1.06B | 0.76% |
| BILZ | -5.41% | $827.73M | 0.14% |
| XHLF | -5.34% | $1.73B | 0.03% |
| STOT | -5.33% | $253.88M | 0.45% |
| XBIL | -4.66% | $783.84M | 0.15% |
| GBIL | -4.59% | $6.37B | 0.12% |
| ULST | -4.45% | $658.54M | 0.2% |
| KMLM | -4.25% | $187.66M | 0.9% |
| IBTF | -4.17% | $2.02B | 0.07% |
| XONE | -4.05% | $585.85M | 0.03% |
Current Value
$1.231 Year Return
Current Value
$1.231 Year Return
